Risiko telogen effluvium pada pasien pasca-COVID-19

Authors

  • Anggita Tamaro Tarumanagara University
  • Sukmawati Tansil Tan Universitas Tarumanagara

Keywords:

COVID-19, pull-test, hair loss, telogen effluvium

Abstract

Pendahuluan: Novel coronavirus disease (COVID-19) merupakan penyakit infeksi yang disebabkan oleh severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Salah satu contoh gejala pasca-COVID adalah kerontokan rambut (telogen effluvium). Oleh karena itu COVID-19 banyak dikaitkan dengan kejadian telogen effluvium. Tujuan dari penelitian ini adalah untuk mencari hubungan antara kejadian pasca-infeksi COVID-19 dengan telogen effluvium pada pasien Klinik Sukma.

Metode: Metode yang digunakan pada penelitian ini adalah chi-square dengan cara membagikan kuesioner dan melakukan pull test. Sampel diambil secara consecutive sampling, kemudian dianalisis menggunakan Pearson’s chi-square dengan Yates’ correction.

Hasil: Jumlah pasien pasca-COVID-19 dengan kejadian rambut rontok sebesar 35 (55,6%). Tidak dapat hubungan yang bermakna secara statistik antara infeksi COVID-19 dengan kejadian rambut rontok (p=0,471). Namun demikian, orang yang terinfeksi COVID-19 berisiko 1,2 kali lebih besar untuk mengalami kerontokan rambut.

Simpulan: Dapat disimpulkan bahwa pasien pasca-COVID-19 berisiko terkena telogen effluvium dan dibutuhkan analisis multivariat pada variabel faktor lainnya. 

Downloads

Download data is not yet available.

References

Menaldi SL, Bramono K, Indriatmi W. Buku ilmu penyakit kulit dan kelamin. 7th ed. Jakarta: Badan Penerbit FKUI; 2019. P. 363-5.

Liyanage D, Sinclair R. Telogen effluvium. Cosmetics. 2016; 3(2):13.

Wolff H, Fischer TW, Blume-Peytavi U. The diagnosis and treatment of hair and scalp diseases. Dtsch Arztebl Int. 2016 May 27;113(21):377-86.

Dhama K, Khan S, Tiwari R, Sircar S, Bhat S, Malik YS, et al. Coronavirus Disease 2019-COVID-19. Clin Microbiol Rev. 2020 Jun 24;33(4):e00028-20.

Lotfi M, Hamblin MR, Rezaei N. COVID-19: Transmission, prevention, and potential therapeutic opportunities. Clin Chim Acta. 2020 Sep;508:254-66.

World Health Organization (WHO) Emergency Committee. Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV) [Internet]. 2020 [cited 2023 Apr 4]. Available from: https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov)

The Lancet. Facing up to long COVID. The Lancet. 2020 Dec;396(10266):1861.

Aksoy H, Yıldırım UM, Ergen P, Gürel MS. COVID-19 induced telogen effluvium. Dermatol Ther. 2021 Nov;34(6):e15175.

McDonald KA, Shelley AJ, Colantonio S, Beecker J. Hair pull test: Evidence-based update and revision of guidelines. J Am Acad Dermatol. 2017 Mar;76(3):472-7.

Wolff K, Johnson RA, Saavedra AP, Roh EK. Fitzpatrick’s color atlas and synopsis of clinical dermatology. 8th ed. USA: McGraw-Hill Education; 2017. p. 794-6.

Wei N, Elbogen E, Dan J, Chessky A, Rivera-Oyola R, Lebwohl M, et al. Telogen effluvium in patients recovering from COVID-19. SKIN The Journal of Cutaneous Medicine, 5(5):533-7.

Inamadar AC. Covid Induced Telogen Effluvium (CITE): An insigh. Indian Dermatol Online J. 2022 Jun 24;13(4):445-8.

Aksoy H, Yıldırım UM, Ergen P, Gürel MS. COVID-19 induced telogen effluvium. Dermatol Ther. 2021 Nov 1;34(6).

Monari P, Gualdi G, Bettoni G, Costa R, Ragni G, Zani F, et al. Post-SARS-CoV-2 acute telogen effluvium: An expected complication. J Clin Med. 2022 Feb 24;11(5):1234.

Seyfi S, Alijanpour R, Aryanian Z, Ezoji K, Mahmoudi M. Prevalence of telogen effluvium hair loss in COVID-19 patients and its relationship with disease severity. J Med Life. 2022 May 1;15(5):631-4.

Sharquie KE, Jabbar RI. COVID-19 infection is a major cause of acute telogen effluvium. Irish Journal of Medical Science (1971 -). 2022 Aug 31;191(4):1677-81.

Hernández Arroyo J, Izquierdo-Condoy JS, Ortiz-Prado E. A case series and literature review of telogen effluvium and alopecia universalis after the administration of a heterologous COVID-19 vaccine scheme. Vaccines (Basel). 2023 Feb 15;11(2):444.

Miyazato Y, Morioka S, Tsuzuki S, Akashi M, Osanai Y, Tanaka K, et al. Prolonged and late-onset symptoms of coronavirus disease 2019. Open Forum Infect Dis. 2020 Oct 21;7(11):ofaa507.

Jimeno-Almazán A, Pallarés JG, Buendía-Romero Á, Martínez-Cava A, Franco-López F, Sánchez-Alcaraz Martínez BJ, et al. Post-COVID-19 syndrome and the potential benefits of exercise. Int J Environ Res Public Health. 2021 May 17;18(10):5329.

Published

2023-12-31

How to Cite

1.
Tamaro A, Tan ST. Risiko telogen effluvium pada pasien pasca-COVID-19. DJM [Internet]. 2023 Dec. 31 [cited 2024 Apr. 28];22(3):190-8. Available from: https://mx2.atmajaya.ac.id/index.php/damianus/article/view/4324
Abstract views: 56 | PDF downloads: 29